Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Standardizing Prurigo Control Assessment Globally: Linguistic Validation and Cross-cultural Adaptation of Prurigo Control Test in 18 Languages.

Acta dermato-venereologica·2026
Same author

A Real-World Cross-Sectional Study on Suspected Mast Cell Activation Syndrome: Multiple Heterogeneous Symptoms Identified.

Clinical and translational allergy·2026
Same author

Outcomes and prognostic factors in patients with systemic mastocytosis and an associated myeloid neoplasm: an international ECNM registry study.

Journal of hematology & oncology·2026
Same author

Psychometric evaluation of the Mastocytosis Symptom Severity Daily Diary (MS2D2) in adults with nonadvanced systemic mastocytosis (NonAdvSM).

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation·2026
Same author

Reply to "Chronic Spontaneous Urticaria: The Most Common MCAS-Like Disease".

The journal of allergy and clinical immunology. In practice·2026
Same author

Differential susceptibility of hair colour changes after barzolvolimab.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026

相关实验视频

Updated: Jun 5, 2025

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.2K

乳腺细胞瘤控制测试:患者报告的结果衡量评估疾病控制.

Frank Siebenhaar1, Senan Sofi1, Sophia Neisinger1

  • 1Institute of Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Fraunhofer Insititute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany.

The journal of allergy and clinical immunology. In practice
|December 5, 2024
PubMed
概括

一个新的巨细胞瘤控制试验 (MCT) 有效地测量了非晚期巨细胞瘤患者的疾病控制. 这种经过验证的患者报告结果指标 (PROM) 有助于在临床实践中监测症状和治疗疗效.

关键词:
控制试验 控制试验 控制试验影响分析 影响分析巨细胞形成是巨细胞形成的.生活质量生活的质量.症状 症状 症状

更多相关视频

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
06:28

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

8.3K
High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids
06:25

High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids

Published on: June 14, 2021

5.2K

相关实验视频

Last Updated: Jun 5, 2025

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.2K
E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
06:28

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

8.3K
High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids
06:25

High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids

Published on: June 14, 2021

5.2K

科学领域:

  • 血液学 血液学 血液学
  • 在瘤学瘤学.
  • 患者报告的结果

背景情况:

  • 巨细胞症涉及器官中瘤巨细胞的扩张,导致各种症状.
  • 目前,缺乏用于控制乳腺细胞瘤疾病的经过验证的患者报告结果指标 (PROM).

研究的目的:

  • 开发和验证乳腺细胞瘤控制试验 (MCT) 以评估非晚期乳腺细胞瘤的疾病控制.

主要方法:

  • 通过文献审查,患者访谈和专家意见生成潜在项目.
  • 使用影响分析,项目间相关性,专家评价和认知总结来减少和选择项目.
  • 验证了MCT的内部一致性,测试-重新测试可靠性,收有效性,已知组有效性和ROC分析.

主要成果:

  • 最后的5项MCT显示了有效的总分数,具有高的内部一致性和测试重试可靠性.
  • 收性和已知组有效性与相关措施有很强的相关性.
  • ROC分析表明,良好的疾病控制的截止值为≥13分.

结论:

  • MCT是一种疾病特异性,有效和可靠的PROM,用于非晚期乳腺细胞瘤的成年患者.
  • 在常规护理和临床试验中,MCT可用于测量和监测疾病控制.